Stifel Nicolaus Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price

Arvinas (NASDAQ:ARVN) had its target price dropped by equities researchers at Stifel Nicolaus from $63.00 to $51.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 188.62% from the stock’s current price.

ARVN has been the topic of several other reports. Barclays cut their price objective on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. BTIG Research began coverage on shares of Arvinas in a research note on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price for the company. Wedbush reiterated an “outperform” rating and set a $57.00 price objective on shares of Arvinas in a research note on Tuesday. HC Wainwright reiterated a “buy” rating and set a $87.00 price objective on shares of Arvinas in a research note on Wednesday, December 11th. Finally, Stephens began coverage on shares of Arvinas in a research note on Monday, November 18th. They set an “overweight” rating and a $55.00 price objective for the company. One analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $59.58.

Arvinas Stock Performance

Shares of NASDAQ:ARVN opened at $17.67 on Wednesday. The firm has a market cap of $1.21 billion, a PE ratio of -3.78 and a beta of 1.88. The firm’s 50 day simple moving average is $19.04 and its 200-day simple moving average is $23.28. Arvinas has a one year low of $16.61 and a one year high of $53.08.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.44. During the same quarter in the previous year, the business earned ($2.53) EPS. Equities research analysts predict that Arvinas will post -3.22 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. nVerses Capital LLC purchased a new position in Arvinas in the third quarter valued at $39,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after buying an additional 440 shares in the last quarter. KBC Group NV increased its holdings in Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after buying an additional 1,255 shares in the last quarter. Quantbot Technologies LP increased its holdings in Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after buying an additional 2,601 shares in the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in Arvinas by 37.0% in the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock valued at $164,000 after buying an additional 1,798 shares in the last quarter. Hedge funds and other institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.